Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA (pembrolizumab), the companys anti-PD-1
(programmed death receptor-1) therapy, at a fixed dose of 200 mg every
three weeks, for the treatment of patients with recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC) with disease progression
on or after platinum-containing chemotherapy.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor:Teri Loxam, 908-740-1898orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more